Attorney Docket No. 9950-0002

Group Art Unit: 1644

Examiner: M. Dibrino

PATENT

TECH CENTER 1600/2900 OCT 1 2 2001

States Postal Service as first class mail in an envelope addressed to Commissioner for Patents! Washington, DC 20231" on

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

In Re Application of:

ULRICH et. al.

U.S. Serial No.: 09/402,273

U.S. Filing Date: December 13, 1999

International Application No.: PCT/EP98/02138

I hereby certify that this correspondence is being deposited with the United

International Filing Date: April 3, 1998

Title: ALLERGEN FORMULATION

AMENDMENT UNDER 37 CFR § 1.111

Commissioner for Patents Washington, DC 20231

Sir:

Submitted herewith for the subject application is and Amendment in response to the Office Action dated July 7, 2001, along with copies of references to which are referred in the Amendment.

No additional amendment fee is required.

The Commissioner is hereby authorized to charge any fees under 37 C.F.R. §§ 1.16 and 1.17 which may be required by this paper, or to credit any overpayment, to Deposit Account No. 18-0580. A duplicate copy of this sheet is enclosed.

Respectfully submitted,

Date

By:

Dianne E. Reed

Registration No. 31,292

REED & ASSOCIATES 800 Menlo Avenue, Suite 210 Menlo Park, California 94025 (650) 330-0900 Telephone (650) 330-0980 Facsimile

I hereby certify that this correspondence is being deposited with the United \$tates Postal Service as first class mail in an envelope addressed to

Attorney Docket No. 9950-0002 Serial No. 09/402,273

Commissioner for Patents, Washington, P.C.

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

In Re Application of:

ULRICH et al.

U.S. Serial No.: 09/402,273

Group Art Unit: 1644

U.S. Filing Date: December 13, 1999

Examiner: M. Dibrino

International Application No.: PCT/EP98/02138

International Filing Date: 03 April 1998

Title: ALLERGEN FORMULATION

AMENDMENT UNDER 37 C.F.R. § 1.111

Commissioner for Patents Washington, D.C. 20231

Sir:

This is in response to the Office Action in the above-identified case, mailed on July 7, 2001. Reconsideration of the application in view of the following remarks and amendments is respectfully requested.

AMENDMENTS

IN THE CLAIMS:

Please cancel claims 3 and 9-14 without prejudice.

Please amend claim 1 as indicated in Appendix A. The amended claim reads as

follows:

1. (Amended) A pharmaceutical composition capable of selectively enhancing TH₁ response comprising tyrosine, an optionally modified allergen or allergen extract, and 3-DMPL.